Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1982 1
1986 1
1987 4
1988 1
1989 2
1995 2
1996 2
1999 1
2000 4
2001 5
2002 5
2003 3
2004 1
2005 1
2007 1
2008 3
2009 1
2010 4
2012 2
2013 2
2014 2
2015 1
2017 3
2018 2
2019 2
2020 1
2021 1
2022 1
2023 1
2025 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

59 results

Results by year

Filters applied: . Clear all
Page 1
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 Diabetes.
Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE Investigators. Agarwal R, et al. N Engl J Med. 2025 Aug 7;393(6):533-543. doi: 10.1056/NEJMoa2410659. Epub 2025 Jun 5. N Engl J Med. 2025. PMID: 40470996 Clinical Trial.
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Torres VE, et al. N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4. N Engl J Med. 2017. PMID: 29105594 Free article. Clinical Trial.
COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
Agarwal R, Green JB, Heerspink HJL, Mann JFE, McGill JB, Mottl AK, Rosenstock J, Rossing P, Vaduganathan M, Brinker M, Edfors R, Li N, Scheerer MF, Scott C, Nangaku M; CONFIDENCE investigators. Agarwal R, et al. Nephrol Dial Transplant. 2025 Aug 1;40(8):1559-1569. doi: 10.1093/ndt/gfaf022. Nephrol Dial Transplant. 2025. PMID: 39916475 Free PMC article. Clinical Trial.
Multicenter Randomized Controlled Trial of Vitamin K Antagonist Replacement by Rivaroxaban with or without Vitamin K2 in Hemodialysis Patients with Atrial Fibrillation: the Valkyrie Study.
De Vriese AS, Caluwé R, Pyfferoen L, De Bacquer D, De Boeck K, Delanote J, De Surgeloose D, Van Hoenacker P, Van Vlem B, Verbeke F. De Vriese AS, et al. Among authors: van vlem b. J Am Soc Nephrol. 2020 Jan;31(1):186-196. doi: 10.1681/ASN.2019060579. Epub 2019 Nov 8. J Am Soc Nephrol. 2020. PMID: 31704740 Free PMC article. Clinical Trial.
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF, Kitzman DW, Kohan D, Makino H, McMurray JJV, Melnick JZ, Miller MG, Pergola PE, Perkovic V, Tobe S, Yi T, Wigderson M, de Zeeuw D; SONAR Committees and Investigators. Heerspink HJL, et al. Lancet. 2019 May 11;393(10184):1937-1947. doi: 10.1016/S0140-6736(19)30772-X. Epub 2019 Apr 14. Lancet. 2019. PMID: 30995972 Clinical Trial.
Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.
Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe SM, Grönhagen-Riska C, De Lima JJ, Lins R, Mayer G, McMahon AW, Parving HH, Remuzzi G, Samuelsson O, Sonkodi S, Sci D, Süleymanlar G, Tsakiris D, Tesar V, Todorov V, Wiecek A, Wüthrich RP, Gottlow M, Johnsson E, Zannad F; AURORA Study Group. Fellström BC, et al. N Engl J Med. 2009 Apr 2;360(14):1395-407. doi: 10.1056/NEJMoa0810177. Epub 2009 Mar 30. N Engl J Med. 2009. PMID: 19332456 Free article. Clinical Trial.
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.
Mottl A, Scott C, Green JB, Heerspink HJL, Mann JFE, McGill JB, Nangaku M, Rosenstock J, Rossing P, Li L, Li N, Vaduganathan M, Agarwal R; CONFIDENCE Trial Investigators. Mottl A, et al. J Am Soc Nephrol. 2025 Nov 6. doi: 10.1681/ASN.0000000928. Online ahead of print. J Am Soc Nephrol. 2025. PMID: 41196655 No abstract available.
Immunosuppression in pancreas transplantation: the Euro SPK trials and beyond.
Malaise J, De Roover A, Squifflet JP, Land W, Neuhaus P, Pratschke J, Kahl A, Pascher A, Boas-Knoop S, Arbogast H, Hoffmann J, Illner WD, Seissler, Schlamp, Viebahn, Wunsch, Hajt, Klar E, Scharek W, Hopt, Pisarski P, Drognitz O, Thurow C, Dette K, Bechstein WO, Woeste G, Klempnauer J, Becker T, Lück, Neipp, Königsrainer A, Steurer W, Margreiter R, Mark, Bonatti, Saudek F, Boucek P, Adamec M, Havrdova T, Koznarova R, Vanrenterghem Y, Pirenne J, Maes B, Kuypers D, Coosemans W, Evenepoel P, van Ophem D, Marcelis V, van Vlem, Peeters, de Hemptinne, de Roose, Fernandez-Cruz L, Ricart MJ, Nakache R, Morel P, Berney T, Demuylder S; Euro SPK Study Group. Malaise J, et al. Among authors: van vlem. Acta Chir Belg. 2008 Nov-Dec;108(6):673-8. doi: 10.1080/00015458.2008.11680314. Acta Chir Belg. 2008. PMID: 19241916 Review.
59 results